Safety is the biggest concern for the FDA. How effective TPM opioid patches are is very much secondary to them. This means more testing IMO pre and post approval to be able to market the product as a safer alternative.
Ann: FDA meeting provides guidance for TPM/Oxymorphone patch, page-4
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
-0.001(10.0%) |
Mkt cap ! $14.28M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $2.55K | 511.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 26 | 18250625 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 27692966 | 23 |
View Market Depth
| Last trade - 12.03pm 25/07/2025 (20 minute delay) ? |
| AVE (ASX) Chart |